On September 19, Ionis Pharmaceuticals fell 5.01% in regular trading, trading at $44.41/share, with turnover of $1.49 billion, extending a prolonged downtrend.

The decline reflects continued fallout from back-to-back failures in the company's cardiovascular pipeline. On September 8, pelacarsen, co-developed with Novartis for cardiovascular disease, failed to meet its primary endpoint in a late-stage trial, triggering a 13% pre-market plunge. Earlier in July, Eplontersen, partnered with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, also failed its Phase 3 primary efficacy endpoint, causing shares to drop over 20% in a single session. These consecutive setbacks have severely eroded investor confidence in the company's core R&D capabilities.

Adding to the pressure, Bank of America cut its price target from $93 to $91, while TD Cowen lowered its target from $108 to $94, reflecting deteriorating institutional sentiment. The stock has fallen sharply from levels above $80 earlier this year despite positive developments including FDA approval of Zanvastro for Alexander disease and strong Q1 revenue of $246 million that beat estimates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)